"Glucosides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D005960
|
| MeSH Number(s) |
D09.408.348
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Glucosides".
Below are MeSH descriptors whose meaning is more specific than "Glucosides".
This graph shows the total number of publications written about "Glucosides" by people in this website by year, and whether "Glucosides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 |
| 1994 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 2 | 1 | 3 |
| 2015 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 2 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glucosides" by people in Profiles.
-
In CKD, the effect of dapagliflozin on kidney outcomes did not vary by T2DM status or CKD cause. Ann Intern Med. 2021 05; 174(5):JC53.
-
Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart?Failure and Reduced Ejection Fraction. J Am Coll Cardiol. 2021 01 26; 77(3):243-255.
-
Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int. 2021 03; 99(3):750-762.
-
Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes? Lancet Diabetes Endocrinol. 2020 07; 8(7):553-555.
-
Effect of liquiritin on neuroendocrine-immune network in menopausal rat model. Phytother Res. 2020 Oct; 34(10):2665-2674.
-
Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity? Cardiovasc Drugs Ther. 2019 02; 33(1):87-95.
-
Deglycosylation of wogonoside enhances its anticancer potential. J Cancer Res Ther. 2018 Sep; 14(Supplement):S594-S599.
-
A surface magnetic imprinted polymers as artificial receptors for selective and efficient capturing of new neuronal nitric oxide synthase-post synaptic density protein-95 uncouplers. J Pharm Biomed Anal. 2018 May 30; 154:180-190.
-
Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page. Circulation. 2018 01 09; 137(2):130-133.
-
Dapagliflozin-citric acid cocrystal showing better solid state properties than dapagliflozin. Eur J Pharm Sci. 2017 Jun 15; 104:255-261.